Hereditary Amyloid Neuropathy Research Study (HAPPIN Study)
First Choice Neurology is pleased to announce the launch of the nation’s first research study of the prevalence of “hereditary amyloid neuropathy”.
HAPPIN Study
The HAPPIN Study is research for Hereditary Amyloid Polyneuropathy Prevalence in Idiopathic Neuropathy.
Neuropathy is a common neurologic disorder whereby patients experience numbness, tingling, weakness, unexplained pain of the extremities. Common causes including diabetes, chronic disease, cancer, HIV, and other metabolic disorders. Neuropathy leads to significant pain, weakness and overall functional disability. If it affects the heart or autonomic system, it can also be life-threatening.
Over 50% of the cases are idiopathic, meaning of unknown cause. It is thought that a significant percentage of those cases are hereditary, and may be due to the deposition of amyloid protein on peripheral nerves.
Most cases of hereditary amyloid neuropathy go undiagnosed and cause significant disability.
First Choice Neurology HAPPIN Research Study
For the first time ever, the doctors at First Choice Neurology are evaluating a large group of patients with idiopathic neuropathy to determine if they possess a hereditary marker for amyloid neuropathy, FDA-approved treatment can now be offered.
The noninvasive study involves patients providing a small sample of saliva which is analyzed by a research lab.
Principal investigator, Dr. Jeffrey Gelblum, explains, “This is a very exciting time in the field of neurology whereby we can harness the information in our large medical database to find those patients who might respond to new disease-modifying therapies.”
Study participants are provided the saliva test free of charge, as all costs are covered by the research sponsor, Ambry Genetics Laboratories.
This large study is expected to conclude within the next 12 months, with findings to be presented at a scientific symposium in 2020.
For more information, contact First Choice Neurology, or the principal investigator Dr. Gelblum, jgelblum@fcneurology.net
Questions About the HAPPIN Study
What is the HAPPIN Study?
What are you looking for in the HAPPIN study?
How many patients will be participating in the HAPPIN study?
How will you evaluate patients for the HAPPIN study?
What happens when a patient has a positive test result?
Who is involved in the HAPPIN study?
About Dr. Jeffrey Gelblum
Dr. Jeffrey Gelblum has successfully treated thousands of patients over a quarter-century, from South Florida, and around the world. He is considered a global thought leader in the neurologic treatment of dementia, seizure disorders, Parkinson’s, Familial Amyloid Polyneuropathy, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas.
Dr. Gelblum maintains numerous research FDA-sponsored affiliations, providing patients immediate access to promising new treatment protocols. His practice maintains academic affiliation with the medical residency programs of Nova Southeast and Florida International University. He trains future neurologists, so it is not unusual to encounter student doctors in the office.
Dr. Gelblum serves as an expert consultant to the State of Florida and Federal Court system on matters of neurologic injury and disability. He is active in multiple community outreach programs to educate the public regarding care and treatment of neurologic disorders. He has pioneered the use of Telehealth and other e-medicine technology to provide patients instant medical access. Complementary modalities and alternative care are part of his holistic approach to successful neurologic care.
About Ambry Genetics Laboratories
Ambry Genetics Laboratories is committed to advancing science by continually optimizing the methodology of detecting variants in order to bring you the most comprehensive test results possible. They led the largest study of its kind (20,000 cases) to illustrate why Ambry’s testing methodology is unmatched in accuracy and specificity. (Mu W, et al., November 2016) and they are the only lab with established and published criteria for validating genes and they continually keep the tests up-to-date and clinically relevant as new genes are identified. When it comes to making important medical management decisions, Ambry Genetics Laboratories believes patients would choose the most reliable and comprehensive testing for themselves and their families.
Contact for the Hereditary Amyloid Neuropathy Research Study (HAPPIN Study)
Dr. Jeffrey Gelblum
Principal Investigator
Phone: (305) 936-9393
Email: jgelblum@fcneurology.net
FIRST CHOICE RESEARCH CENTER 26
Aventura Medical Tower
2801 NE 213 Street, Suite 1004
Aventura, FL 33180
(305) 936-9393